AFFIRMO

Atrial fibrillation (AF) is an irregular and often very rapid heart rhythm (arrhythmia) that can lead to blood clots in the heart. AF increases the risk of stroke, heart failure and other heart-related complications. The prevalence of AF is growing amongst Europe’s elderly population, often facing multimorbidity. The management of AF, therefore, requires a holistic approach rather than a single-disease approach with fragmented care.

AFFIRMO aims to move from fragmentation to an integrated care strategy designed to be patient-centred. AFFIRMO’s care pathway will improve the clinical management of older AF patients, taking into account personal treatment preferences, social context, polypharmacy etc. It will enable synergies and cooperation among the different health disciplines involved and shared decision-making with the patient. AFFIRMO’s care pathway will rely on a digital platform developed to assist physicians in applying and tailoring a personalised care strategy.

i~HD is a consortium partner and handles all legal and ethical challenges. This involves leading work on information governance, GDPR compliance and data sharing.

AFFIRMO has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 899871. It started on 1 May 2021 and will end on 30 April 2026.